Infant Bacterial Therapeutics AB (IBT B) NPV B

Sell:39.80 SEKBuy:40.50 SEK0.30 SEK (0.74%)

Prices delayed by at least 15 minutes
Sell:39.80 SEK
Buy:40.50 SEK
Change:0.30 SEK (0.74%)
Deal now
Prices delayed by at least 15 minutes
Sell:39.80 SEK
Buy:40.50 SEK
Change:0.30 SEK (0.74%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Key people

Peter Rothschild
Chairman of the Board
Staffan Stroemberg
Chief Executive Officer
Maria Ekdahl
Chief Financial Officer
Anders Kronstrom
Chief Operating Officer
Robert Molander
Chief Commercial Officer
Jonas Rastad
Chief Medical Officer
Margareta Hagman
Independent Director
Eva Iden
Independent Director
Anthon Jahreskog
Independent Director
Kristina Sjoeblom Nygren
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    SE0008015259
  • Market cap
    SEK 529.84m
  • Employees
    9
  • Shares in issue
    13.02m
  • Exchange
    Stockholm Stock Exchange
  • Index
    SX All Share PI Market Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.